PBF-999 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
8	Huntington disease	2

8. Huntington disease

---

Clinical trials : 242 /  Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02907294 (ClinicalTrials.gov)	March 2016	8/3/2016	Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 After Multiple Oral Doses in Healthy Volunteers	Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 (160 mg and 320 mg) After Multiple Oral Doses in Healthy Volunteers	Huntington Disease	Drug: PBF-999 / 160 mg;Drug: PBF-999 / 320 mg;Drug: Placebo	Palobiofarma SL	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Terminated	18 Years	45 Years	Both	8	Phase 1	Spain
2	NCT02208934 (ClinicalTrials.gov)	September 2014	4/8/2014	Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers	Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male Volunteers	Huntington's Disease	Drug: PBF-999;Drug: Placebo	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Palo Biofarma, S.L	Completed	18 Years	45 Years	Male	32	Phase 1	Spain